{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:09:18Z","timestamp":1790665758709,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1016\/j.ejca.2009.10.005","type":"journal-article","created":{"date-parts":[[2009,11,16]],"date-time":"2009-11-16T13:38:23Z","timestamp":1258378703000},"page":"198-206","source":"Crossref","is-referenced-by-count":48,"title":["Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours"],"prefix":"10.1016","volume":"46","clinical-trial-number":[{"clinical-trial-number":"nct00419328","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Vanesa","family":"Gregorc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Citterio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giordano","family":"Vitali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Spreafico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Scifo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Borri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Donadoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilda","family":"Rossoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Corti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Caligaris-Cappio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro Del","family":"Maschio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"De Cobelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Dell\u2019Acqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Troysi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Bruzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Lambiase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Bordignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2009.10.005_bib1","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1073\/pnas.72.9.3666","article-title":"An endotoxin-induced serum factor that causes necrosis of tumours","volume":"72","author":"Carswell","year":"1975","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ejca.2009.10.005_bib2","first-page":"6","article-title":"Efficiency of recombinant human TNF in human cancer therapy","volume":"6","author":"Lejeune","year":"2006","journal-title":"Cancer Immun"},{"key":"10.1016\/j.ejca.2009.10.005_bib3","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/BF00267953","article-title":"A phase I clinical trial of recombinant human tumour necrosis factor given daily for five days","volume":"23","author":"Creaven","year":"1989","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2009.10.005_bib4","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/0277-5379(91)90134-Y","article-title":"Phase I trial of recombinant human tumour necrosis factor alpha in patients with advanced malignancy","volume":"27","author":"Gamm","year":"1991","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2009.10.005_bib5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/BF00570490","article-title":"Phase I study of recombinant human tumour necrosis factor","volume":"20","author":"Kimura","year":"1987","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2009.10.005_bib6","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/BF00877244","article-title":"A phase I pharmacokinetic study of recombinant human tumour necrosis factor administered by a 5-day continuous infusion","volume":"10","author":"Mittelman","year":"1992","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ejca.2009.10.005_bib7","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/BF02170889","article-title":"A phase I trial of recombinant tumour necrosis factor (rTNF) administered by continuous intravenous infusion in patients with disseminated malignancy","volume":"1","author":"Schwartz","year":"1989","journal-title":"Biotherapy"},{"key":"10.1016\/j.ejca.2009.10.005_bib8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/BF00397922","article-title":"Phase-I trial of intravenous continuous infusion of tumour necrosis factor in advanced metastatic carcinomas","volume":"115","author":"Wiedenmann","year":"1989","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ejca.2009.10.005_bib9","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1200\/JCO.1996.14.10.2653","article-title":"Isolated limb perfusion with high-dose tumour necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial","volume":"14","author":"Eggermont","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2009.10.005_bib10","first-page":"2357","article-title":"Augmented capillary leak during isolated hepatic perfusion (IHP) occurs via tumour necrosis factor-independent mechanisms","volume":"4","author":"Alexander","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2009.10.005_bib11","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/81183","article-title":"Enhancement of tumor necrosis factor alpha antitumour immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13)","volume":"18","author":"Curnis","year":"2000","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.ejca.2009.10.005_bib12","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1196\/annals.1322.011","article-title":"Tumour vascular targeting with tumour necrosis factor alpha and chemotherapeutic drugs","volume":"1028","author":"Corti","year":"2004","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.ejca.2009.10.005_bib13","doi-asserted-by":"crossref","first-page":"47891","DOI":"10.1074\/jbc.M207500200","article-title":"Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif","volume":"277","author":"Colombo","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejca.2009.10.005_bib14","first-page":"867","article-title":"Differential binding of drugs containing the NGR motif to CD13 isoforms in tumour vessels, epithelia, and myeloid cells","volume":"62","author":"Curnis","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2009.10.005_bib15","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1172\/JCI0215223","article-title":"Improving chemotherapeutic drug penetration in tumours by vascular targeting and barrier alteration","volume":"110","author":"Curnis","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejca.2009.10.005_bib16","doi-asserted-by":"crossref","first-page":"158s","DOI":"10.1200\/jco.2008.26.15_suppl.3521","article-title":"Phase I and DCE-MRI evaluation of NGR-TNF, a novel vascular targeting agent, in patients with solid tumours (EORTC 16041)","volume":"26","author":"van Laarhoven","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2009.10.005_bib17","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/jmri.1880070318","article-title":"Probing tumor microvascularity by measurement, analysis and display of contrast agent uptake kinetics","volume":"7","author":"Parker","year":"1997","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.ejca.2009.10.005_bib18","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S","article-title":"Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols","volume":"10","author":"Tofts","year":"1999","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.ejca.2009.10.005_bib19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1109\/MEMB.2004.1360410","article-title":"Dynamic magnetic resonance imaging of tumour perfusion. Approaches and biomedical challenges","volume":"23","author":"Collins","year":"2004","journal-title":"IEEE Eng Med Biol Mag"},{"key":"10.1016\/j.ejca.2009.10.005_bib20","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/ncponc0663","article-title":"Drug insight: vascular disrupting agents and angiogenesis\u2013novel approaches for drug delivery","volume":"3","author":"Cooney","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.ejca.2009.10.005_bib21","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrd819","article-title":"Angiogenesis modulation in cancer research: novel clinical approaches","volume":"1","author":"Cristofanilli","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ejca.2009.10.005_bib22","doi-asserted-by":"crossref","first-page":"6616","DOI":"10.1158\/0008-5472.CAN-04-0401","article-title":"Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies","volume":"64","author":"Bocci","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2009.10.005_bib23","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.clon.2004.11.011","article-title":"Vascular disrupting agents: a new class of drug in cancer therapy","volume":"17","author":"Gaya","year":"2005","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ejca.2009.10.005_bib24","series-title":"Biologic therapy of cancer: principles and practice","first-page":"329","article-title":"Biologic therapy with TNF: systemic administration and isolation-perfusion","author":"Fraker","year":"1995"},{"issue":"Suppl. 1","key":"10.1016\/j.ejca.2009.10.005_bib25","first-page":"21","article-title":"Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study","volume":"4","author":"Lienard","year":"1994","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejca.2009.10.005_bib26","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1172\/JCI694","article-title":"Shedding kinetics of soluble tumor necrosis factor (TNF) receptors after systemic TNF leaking during isolated limb perfusion","volume":"101","author":"Aderka","year":"1998","journal-title":"J Clin Invest"},{"issue":"12","key":"10.1016\/j.ejca.2009.10.005_bib27","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1158\/1078-0432.CCR-07-0238","article-title":"Imaging tumour vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging","volume":"13","author":"Jackson","year":"2007","journal-title":"Clin Cancer Res"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804909007308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804909007308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,15]],"date-time":"2018-12-15T05:54:22Z","timestamp":1544853262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804909007308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S0959804909007308"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2009.10.005","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}